Vimarsana
Biggest News Aggregation in the World

Page 2 - Clinical Presentation News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Clinical Presentation. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Clinical Presentation Today - Breaking & Trending Today

Latest Clinical Evidence Presented at APWCA's Wound Week™ 2023 Illustrates the Significant and New Clinical Utility of the MolecuLight Point-of-Care Imaging Platform - Vimarsana News

Latest Clinical Evidence Presented at APWCA's Wound Week™ 2023 Illustrates the Significant and New Clinical Utility of the MolecuLight Point-of-Care Imaging Platform

/PRNewswire/ -- MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of wounds containing elevated bacterial loads,...

XACDURO®, The First and Only Antibiotic Developed to Target Acinetobacter, Now Available to Treat Hospital-Acquired Bacterial Pneumonia (HABP) and Ventilator-Associated Bacterial Pneumonia (VABP) in Adults - Vimarsana News

XACDURO®, The First and Only Antibiotic Developed to Target Acinetobacter, Now Available to Treat Hospital-Acquired Bacterial Pneumonia (HABP) and Ventilator-Associated Bacterial Pneumonia (VABP) in Adults

XACDURO is a new FDA-approved treatment used to fight against HABP/VABP infections caused by isolates of Acinetobacter baumannii-calcoaceticus complex, which can include those resistant to...

XACDURO®, The First and Only Antibiotic Developed to Target Acinetobacter, Now Available to Treat Ho - Vimarsana News

XACDURO®, The First and Only Antibiotic Developed to Target Acinetobacter, Now Available to Treat Ho

XACDURO is a new FDA-approved treatment used to fight against HABP/VABP infections caused by isolates of Acinetobacter baumannii-calcoaceticus complex, which can include those resistant to carbapenems (CRAB).In the U.S., it is estimated there are more than 40,000 cases of Acinetobacter each year and approximately 40...

What is Cholesteryl Ester Storage Disease? - Vimarsana News

What is Cholesteryl Ester Storage Disease?

​​​​​​Cholesteryl Ester Storage Disease (CESD) is a rare autosomal recessive multisystem condition that belongs to the lysosomal storage disorders family.

In-Vitro Inflammatory Bowel Disease Diagnostic Market Size - Vimarsana News

In-Vitro Inflammatory Bowel Disease Diagnostic Market Size

The global in-vitro inflammatory bowel disease diagnostic market is expected to grow at a remarkable CAGR of 4.2 from 2023 to 2030, driven by increasing...